News for Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2024 Earnings Call Transcript March 10, 2025Lineage Cell Therapeutics, Inc. beats earnings expectations.

Cash Position: $47.8 million in cash, cash equivalents, and marketable securities as of December 31, 2024.Revenue (Q4 2024): $2.9 million, an increase from $2.

Mar 10, 2025 / 08:30PM GMTOperator Thank you for standing by. My name is Rochelle, and I will be your conference operator today. At this time, I would like to w

We recently published a list of 7 new stock picks in Brad Gerstner's portfolio. In this article, we are going to take a look at where Lineage Cell Therapeutics, Inc.

Strategists and investors are confident that the new administration will fuel the state of mergers and acquisitions in the United States.

Release Date: November 14, 2024For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Lineage Cell

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NLCTX.A - Lineage Cell Therapeutics IncQ3 2024 Lineage Cell Therapeutics Inc Earnings CallNov 1

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ETCompany ParticipantsIoana Hone - Head of Investor...

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

Sensorineural hearing loss (SNHL) is the most common type of hearing loss, caused by damage to the inner ear (cochlea) or the auditory nerve pathways....

Cash, Cash Equivalents, and Marketable Securities: $38.5 million as of June 30, 2024.Revenue: $1.4 million, a decrease from $3.2 million in the same period in

Aug 08, 2024 / 08:30PM GMTOperator Welcome to the Lineage Cell Therapeutics second quarter 2024 conference call. At this time, all participants are in a listen

Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry...

Autologous Cell Therapy Breakthroughs in Cancer and Autoimmune Disease Treatment...

Insights into Fisher Investments' Latest 13F Filings Ken Fisher (Trades, Portfolio), the CEO and CIO of Fisher Investments, is renowned for his contrarian inve

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A Information ...

Award Will Support 2nd Annual Spinal Cord Injury Investor Symposium To Be Held June 26 and 27, 2024 ...

The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of...

/PRNewswire/ -- The cell therapy market size is expected to grow by USD 31.04 billion from 2022 to 2027. In addition, the momentum of the market will progress...